marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma Balance Sheet 2011-2024 | ALBO
Annual Balance Sheet Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -239 M | -132 M | -164 M | -53.2 M | -28.7 M | -40.8 M | -24.6 M | -39.8 M | -39 M | -38.7 M |
Long Term Debt |
- | 9.62 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | 3.08 M | - | - | - | - | - |
Total Non Current Liabilities |
- | 79.1 M | 53 M | 50 M | 42 K | 359 K | 59 K | 1.01 M | 6.15 M | 7.34 M | 1.14 M |
Total Current Liabilities |
45.3 M | 25.3 M | 18.9 M | 12.8 M | 7.93 M | 12.7 M | 1.81 M | 1.62 M | 2.44 M | 2.78 M | 3.29 M |
Total Liabilities |
126 M | 104 M | 71.9 M | 62.8 M | 7.97 M | 2.43 M | 1.87 M | 2.63 M | 8.59 M | 10.1 M | 4.43 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-301 M | -267 M | -159 M | -96.5 M | -50.4 M | -262 M | -248 M | -230 M | -215 M | -196 M | -175 M |
Total Assets |
302 M | 286 M | 165 M | 185 M | 73.2 M | 28.9 M | 41.4 M | 25.4 M | 41.2 M | 41.1 M | 41.5 M |
Cash and Cash Equivalents |
248 M | 251 M | 132 M | 164 M | 53.2 M | 29.9 M | 5.12 M | 24.6 M | 39.8 M | 39 M | 38.7 M |
Book Value |
176 M | 181 M | 93.2 M | 123 M | 65.3 M | 26.4 M | 39.6 M | 22.8 M | 32.6 M | 31 M | 37.1 M |
Total Shareholders Equity |
176 M | 181 M | 93.2 M | 123 M | 65.3 M | 37 M | -8.74 M | 22.8 M | 32.6 M | 31 M | 37.1 M |
All numbers in USD currency
Quarterly Balance Sheet Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 10.8 M | - | - | - | 3.56 M | - | - | - | 4.19 M | 4.33 M | 200 K | 213 K | - | - | - | - | - | - | - | - | - | - | - | - | 4.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 221 M | 115 M | 113 M | 126 M | 115 M | 106 M | 102 M | 104 M | 104 M | 104 M | 104 M | 71.9 M | 71.9 M | 71.9 M | 71.9 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 7.97 M | 7.97 M | 7.97 M | 7.97 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 15.2 M | 1.87 M | 1.87 M | 1.46 M | 2.16 M | 2.63 M | 2.63 M | 2.63 M | 6.57 M | 8.59 M | 8.59 M | 8.59 M | 9.39 M | 10.1 M | 10.1 M | 10.1 M | 4.64 M | 4.43 M | 4.43 M | 4.43 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -421 M | -383 M | -343 M | -301 M | -290 M | -347 M | -311 M | -267 M | -267 M | -267 M | -267 M | -159 M | -159 M | -159 M | -159 M | -96.5 M | -96.5 M | -96.5 M | -96.5 M | -50.4 M | -50.4 M | -50.4 M | -50.4 M | -25.9 M | -25.9 M | -25.9 M | -25.9 M | -9.6 M | -248 M | -248 M | -252 M | - | -230 M | -230 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 321 M | 229 M | 261 M | 302 M | 296 M | 219 M | 250 M | 286 M | 286 M | 286 M | 286 M | 165 M | 165 M | 165 M | 165 M | 185 M | 185 M | 185 M | 185 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 6.97 M | 41.4 M | 41.4 M | 37.9 M | 21 M | 25.4 M | 25.4 M | 25.4 M | 37 M | 41.2 M | 41.2 M | 41.2 M | 37.3 M | 41.1 M | 41.1 M | 41.1 M | 38.1 M | 41.5 M | 41.5 M | 41.5 M |
Cash and Cash Equivalents |
- | 222 M | 181 M | 217 M | 248 M | 263 M | 186 M | 217 M | 251 M | 251 M | 251 M | 251 M | 132 M | 132 M | 132 M | 132 M | 164 M | 164 M | 164 M | 164 M | 53.2 M | 53.2 M | 53.2 M | 53.2 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 5.12 M | 40.8 M | 40.8 M | 36.9 M | 8.18 M | 24.6 M | 24.6 M | 19.7 M | 35.2 M | 39.8 M | 39.8 M | 35.2 M | 34.3 M | 39 M | 39 M | 34.3 M | 35.1 M | 38.7 M | 38.7 M | 35.1 M |
Book Value |
- | 100 M | 114 M | 148 M | 176 M | 182 M | 114 M | 148 M | 181 M | 181 M | 181 M | 181 M | 93.2 M | 93.2 M | 93.2 M | 93.2 M | 123 M | 123 M | 123 M | 123 M | 65.3 M | 65.3 M | 65.3 M | 65.3 M | 37 M | 37 M | 37 M | 37 M | -8.22 M | 39.6 M | 39.6 M | 36.5 M | 18.9 M | 22.8 M | 22.8 M | 22.8 M | 30.4 M | 32.6 M | 32.6 M | 32.6 M | 27.9 M | 31 M | 31 M | 31 M | 33.4 M | 37.1 M | 37.1 M | 37.1 M |
Total Shareholders Equity |
- | 100 M | 114 M | 148 M | 176 M | 182 M | 114 M | 148 M | 181 M | 181 M | 181 M | 181 M | 93.2 M | 93.2 M | 93.2 M | 93.2 M | 123 M | 123 M | 123 M | 123 M | 65.3 M | 65.3 M | 65.3 M | 65.3 M | 37 M | 37 M | 37 M | 37 M | -8.74 M | 39.6 M | 39.6 M | 36.5 M | -2.33 M | 22.8 M | 22.8 M | 18.9 M | 30.4 M | 32.6 M | 32.6 M | 32.6 M | 31 M | 31 M | 31 M | 27.9 M | 33.4 M | 37.1 M | 37.1 M | 33.4 M |
All numbers in USD currency